Production (Stage)
Fresh Tracks Therapeutics, Inc.
FRTX
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 1,534.57% | -98.77% | -90.22% | 1,871.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | 1,534.57% | -98.77% | -90.22% | 1,871.15% |
| Cost of Revenue | -99.62% | -82.39% | -67.35% | -67.80% | -16.48% |
| Gross Profit | 98.20% | 338.03% | -122.69% | 67.45% | 81.59% |
| SG&A Expenses | -59.34% | 77.22% | -53.74% | -30.75% | 22.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -75.13% | -9.37% | -58.13% | -54.21% | 3.65% |
| Operating Income | 64.03% | 132.87% | -62.14% | 53.85% | 27.15% |
| Income Before Tax | 72.65% | 134.96% | -99.13% | 54.56% | 25.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.65% | 134.96% | -99.13% | 54.56% | 25.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.65% | 131.69% | -99.13% | 54.56% | 25.38% |
| EBIT | 64.03% | 132.87% | -62.14% | 53.85% | 27.15% |
| EBITDA | 64.18% | 133.09% | -62.12% | 53.93% | 27.21% |
| EPS Basic | 86.22% | 115.57% | 10.49% | 67.91% | 40.52% |
| Normalized Basic EPS | 86.22% | 114.61% | 10.48% | 67.91% | 40.88% |
| EPS Diluted | 86.22% | 115.57% | 10.49% | 67.91% | 40.52% |
| Normalized Diluted EPS | 86.22% | 114.61% | 10.48% | 67.91% | 40.88% |
| Average Basic Shares Outstanding | 98.41% | 103.47% | 122.44% | 41.61% | 25.46% |
| Average Diluted Shares Outstanding | 98.41% | 103.47% | 122.44% | 41.61% | 25.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |